FDA Grants Accelerated Approval to Epcoritamab for Relapsed or Refractory Diffuse Large B-cell Lymphoma and High-Grade B-cell Lymphoma

1 year ago

On May 19, 2023, Epcoritamab-bysp (Epkinly, Genmab US, Inc) was granted accelerated approval by the US FDA for the treatment…

Expert Opinion in Multiple Myeloma with Dr. Shaji Kumar

1 year ago

Dr. Richa Parikh interviewed Dr. Shaji Kumar of Mayo Clinic about his recommendations for the treatment of myeloma.

FDA Grants Approval to Avapritinib for Indolent Systemic Mastocytosis

1 year ago

On May 22, 2023, the U.S. Food and Drug Administration approved avapritinib (Ayvakit) for the treatment of adults with indolent…

A Summary of the DACOTA Trial

2 years ago

By Dr. Chepsy Philip Believer's Church Medical College Hospital   Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…

FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Large B-cell Lymphoma

2 years ago

On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved Polatuzumab Vedotin-Piiq in combination with a rituximab product,…

Updated Results from the ASCEMBL Trial

2 years ago

By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the…

AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer

2 years ago

By Dr. Dipesh Uprety Karmanos Cancer Institute   Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the…

The Polarix Trial and the Rise of Polatuzumab-RCHP

2 years ago

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center    Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab,…

Cancer Care in the MENA Region: A Multi-Faceted Approach to Improving Access, Quality, and Patient Outcomes

2 years ago

By Dr. Abdurahman Alloghbi King Khalid University, Saudi Arabia   The Middle East and North Africa (MENA) region spans 22…

Risk Factors for Relapse Among Breast Cancer Patients with Pathological Complete Response (pCR) Post Neoadjuvant Treatment

2 years ago

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Attainment of pathological complete response (pCR) of breast cancer is…